American Society of Hirudotherapy

Pharmacology of recombinant hirudin

Research article published in Seminars in thrombosis and hemostasis (2002)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyGenomics & ProteomicsNowak G · Seminars in thrombosis and hemostasis, 2002

Abstract

Hirudin is the anticoagulative product of the salivary glands of the medical leech Hirudo medicinalis. It is characterized by a direct, bifunctional inhibition mechanism and a high, exclusive specificity and a strong ability to bind to thrombin (tight binding). Further characteristics are the organic-chemical structure of hirudin (peptide), which allows only parenteral administration; the missing metabolism in the organism; and the exclusive glomerular filtration of hirudin in kidneys as the effective elimination mechanism. Recombinant hirudin (r-hirudin) is a product of genetic engineering that is identical to the hirudin found in nature and has the same biochemical and pharmacological characteristics as natural hirudin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAmino Acid SequenceAnimalsDose-Response Relationship, DrugFibrinolytic AgentsGenetic EngineeringHirudin TherapyHirudinsHumansLeechesMolecular Sequence DataProtein Structure, SecondaryProtein Structure, Tertiary

Summary

Hirudin is the anticoagulative product of the salivary glands of the medical leech Hirudo medicinalis. It is characterized by a direct, bifunctional inhibition mechanism and a high, exclusive specificity and a strong ability to bind to thrombin (tight binding).

Why This Matters for Hirudotherapy

This article examines the pharmacology of hirudin, described as the anticoagulative product of the salivary glands of the medicinal leech Hirudo medicinalis, and its recombinant form (r-hirudin), which the abstract states is identical to natural hirudin in biochemical and pharmacological characteristics. The abstract details hirudin's direct bifunctional thrombin inhibition mechanism, high exclusive specificity, tight binding, parenteral-only administration, absence of metabolism in the organism, and exclusive renal elimination via glomerular filtration. This work is directly relevant to hirudotherapy and ASH's domain because it characterizes a specific anticoagulant molecule originating from leech salivary secretions, providing pharmacological knowledge about a well-defined leech-derived agent. However, the scope is limited to the pharmacology of isolated recombinant hirudin and does not address the broader leech salivary secretome, live leech therapy contexts, or clinical outcome data.

Citation

Pharmacology of recombinant hirudin.

Nowak G · Seminars in thrombosis and hemostasis, 2002

DOI

Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.